Skip to main navigation
NantKwest
  • About
    • Company
    • Leadership
    • Board of Directors
  • Technology
    • Platform
    • Manufacturing
    • haNK
    • taNK
    • t-haNK
    • Posters
    • Publications
  • Clinical Trials
    • Pipeline
    • Nant Cancer Vaccine
  • News
    • Press Releases
    • Articles
    • Events
    • Presentations
  • Investors

    Investor Relations

    • Overview
    • Stock Information
      • Stock Quote and Chart
      • Historical Price Lookup
      • Stock Calculator
    • News
    • Events & Presentations
    • Financials
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • Corporate Governance
      • Governance Highlights
      • Management Team
      • Board of Directors
      • Committee Composition
    • Investor FAQs
    • Contact Us
  • Careers
    • Join Our Kwest
    • We’re Hiring
  • Contact
  • Patients
Select Page
  • About
    • Company
    • Leadership
    • Board of Directors
  • Technology
    • Platform
    • Manufacturing
    • haNK
    • taNK
    • t-haNK
    • Presentations & Posters
    • Publications
  • Clinical Trials
    • Pipeline
    • Nant Cancer Vaccine
  • News
    • Press Releases
    • Articles
    • Events
    • Presentations
  • Investors

    Investor Relations

    • Overview
    • Stock Information
      • Stock Quote and Chart
      • Historical Price Lookup
      • Stock Calculator
    • News
    • Events & Presentations
    • Financials
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • Corporate Governance
      • Governance Highlights
      • Management Team
      • Board of Directors
      • Committee Composition
    • Investor FAQs
    • Contact Us
  • Careers
    • Join Our Kwest
    • We’re Hiring
  • Contact
  • Patients

INVESTOR RELATIONS

SEC Filing Details

Document Details

Form
D
Filing Date
Apr 17, 2014
Document Date
Apr 17, 2014
Filing Group
Other
Company
Nantkwest, Inc.
Issuer
NantKwest, Inc.

Filing Formats

View HTML
Download PDF
Download DOC

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Print Page
RSS Feeds
E-mail Alerts

CONTACT NANTKWEST

NK-92 ® CELLS FOR ASSAYS

  • Facebook
  • Twitter
  • LinkedIn
    •  
 © 2021 Nantkwest, Inc.. All Rights Reserved. A member of the NantWorks ecosystem of companies Privacy Policy | Legal Notice | Patent Notice
‘Nantkwest’, ‘aNK’, 'haNK', 'taNK', ‘vaNK’, 't-haNK', 'NK-92', ‘Neukosome’, 'Living Drugs in a Bag', and ‘Nature’s First Responder’ are trademarks or registered trademarks of Nantkwest, Inc.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.